130 related articles for article (PubMed ID: 8840428)
21. [Study on the combined preoperative treatment with CDDP and HCFU for gastric cancer].
Yamaguchi R; Yamaguchi A; Isogai M; Hori A; Kin Y
Gan To Kagaku Ryoho; 1996 Jul; 23(8):1089-91. PubMed ID: 8687229
[No Abstract] [Full Text] [Related]
22. [Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report].
Kobayashi M; Kasakura Y; Fujii M; Mochizuki F; Kochi M; Eguchi T; Imai S
Gan To Kagaku Ryoho; 2001 Apr; 28(4):527-30. PubMed ID: 11329789
[TBL] [Abstract][Full Text] [Related]
23. The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer.
Guo MG; Zheng Q; Cheng Z; Wang Y; Feng CN; Yang Z
Surg Oncol; 2010 Mar; 19(1):1-3. PubMed ID: 19006661
[TBL] [Abstract][Full Text] [Related]
24. [TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator].
Sakuyama T; Takahashi N
Gan To Kagaku Ryoho; 1994 May; 21 Suppl 1():117-21. PubMed ID: 8203923
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
[TBL] [Abstract][Full Text] [Related]
26. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
28. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
[TBL] [Abstract][Full Text] [Related]
29. [Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
Tasaka K; Okada Y; Tomofuji Y; Chinzei T
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1631-5. PubMed ID: 12355951
[TBL] [Abstract][Full Text] [Related]
30. A phase 2 study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly plus biweekly alternating doxorubicin and cisplatin for advanced gastric cancer.
Markman M
J Cancer Res Clin Oncol; 1998; 124(7):353. PubMed ID: 9719497
[No Abstract] [Full Text] [Related]
31. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
32. Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Noh SH; Yoo CH; Chung HC; Roh JK; Shin DW; Min JS
Oncology; 2001; 60(1):24-30. PubMed ID: 11150904
[TBL] [Abstract][Full Text] [Related]
33. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
Persiani R; D'Ugo D; Rausei S; Sermoneta D; Barone C; Pozzo C; Ricci R; La Torre G; Picciocchi A
J Surg Oncol; 2005 Mar; 89(4):227-36; discussion 237-8. PubMed ID: 15726615
[TBL] [Abstract][Full Text] [Related]
34. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
[TBL] [Abstract][Full Text] [Related]
35. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
[TBL] [Abstract][Full Text] [Related]
36. Effects of preoperative chemotherapy on gastric carcinoma: the relationship between histopathologic response and prognosis.
Kumagai K; Ishibashi Y; Yasui A
Clin Ther; 1995; 17(5):936-45. PubMed ID: 8595645
[TBL] [Abstract][Full Text] [Related]
37. UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.
Abe S; Kubota T; Otani Y; Furukawa T; Watanabe M; Kumai K; Kitajima M
Jpn J Cancer Res; 2000 Nov; 91(11):1192-8. PubMed ID: 11092986
[TBL] [Abstract][Full Text] [Related]
38. Proliferation kinetics and prognosis in gastric cancer after resection.
Sendler A; Gilbertz KP; Becker I; Mueller J; Berger U; Fink U; van Beuningen D; Siewert JR
Eur J Cancer; 2001 Sep; 37(13):1635-41. PubMed ID: 11527689
[TBL] [Abstract][Full Text] [Related]
39. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
[TBL] [Abstract][Full Text] [Related]
40. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
